Osteoporosis case manager for patients with hip fractures: Results of a cost-effectiveness analysis conducted alongside a randomized trial

Archives of Internal Medicine

Volumn 169, Issue 1, 2009, Pages 25-31

  Majumdar, Sumit R ^a,c   Lier, Douglas A ^a   Beaupre, Lauren A ^a   Hanley, David A ^b   Maksymowych, Walter P ^a   Juby, Angela G ^a   Bell, Neil R ^a   Morrish, Donald W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CASE MANAGER; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TASK PERFORMANCE;

AGED; AGED, 80 AND OVER; BONE DENSITY; CASE MANAGEMENT; COST SAVINGS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FRACTURE FIXATION, INTRAMEDULLARY; HEALTH CARE COSTS; HIP FRACTURES; HUMANS; INTERVENTION STUDIES; MALE; MARKOV CHAINS; MIDDLE AGED; OSTEOPOROSIS; PROBABILITY; QUALITY OF LIFE; REFERENCE VALUES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58349103330     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.169.1.25     Document Type: Article

References (24)

1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-475.
2. Majumdar SR, Beaupre LA, Harley CH, et al. Using a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med. 2007;167(19):2110-2115.
3. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-1809.
4. Cranney A, Guyatt GH, Griffith L, Wells G, Tugwell P, Rosen C; Osteoporosis Methodology Group and Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis, IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23(4):570-578.
5. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35(5):293-305.
6. Jiang HX, Majumdar SR, Dick DA, et al. Development and initial validation of a risk score for predicting in-hospital and one-year mortality in patients with hip fractures. J Bone Miner Res. 2005;20(3):494-500.
7. Juby AG, de Geus-Wenceslau CM. Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int. 2002;13(3):205-210.
8. Sonnenberg FA, Beck R. Markov models in medical decision-making: a practical guide. Med Decis Making. 1993;13(4):322-338.
9. Tosteson AN, Jönsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int. 2001;12(10):849-857.
10. Johnell O, Jönsson B, Jönsson L, Black D. Cost effectiveness of alendronate for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics. 2003;21(5):305-314.
11. Zethraeus N, Borgström F, Ström O, Kanis J, Jönsson B. Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int. 2007;18(1):9-23.
12. Ström O, Zethraeus N, Borgström F, Johnell O, Jönsson B, Kanis J. IOF cost-effectiveness reference model: background document. International Osteoporosis Foundation. http://www.iofbonehealth.org/health- professionals/health-economics/cost-effectiveness-model.html. Accessed May 5, 2008.
13. Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int. 2001;12(4):271-278.
14. Tonino RP, Meunier PJ, Emkey RD, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2000;85(9):3109-3115.
15. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189-1199.
16. Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142(9):734-741.
17. Alberta Health Care Insurance Plan. Schedule of Medical Benefits (Procedures and Price List). Edmonton, AB, Canada: Alberta Health and Wellness; 2006.
18. Drug Benefits List. Edmonton, AB: Alberta Health and Wellness; 2007.
19. Health Costing in Alberta. Annual Report. Edmonton, AB: Alberta Health and Wellness; 2006.
20. Resource Intensity Weights and Expected Length of Stay. Ottawa, ON: Canadian Institute for Health Information; 2005.
21. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ. Incidence of clinically diagnosed vertebral fractures: a population based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992;7(2):221-227.
22. Life Tables: Canada, Provinces and Territories, 2000-2002 (84-537-XIE). Ottawa, ON: Statistics Canada; 2006.
23. Dong H, Buxton M. Early assessment of the likely cost-effectiveness of a new technology: a Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. Int J Technol Assess Health Care. 2006;22(2):191-202.
24. Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003;14(9):722-727.